Inhibition of FLT3 in MLL: Validation of a therapeutic target identified by gene expression based classification
Top Cited Papers
- 28 February 2003
- journal article
- research article
- Published by Elsevier BV in Cancer Cell
- Vol. 3 (2), 173-183
- https://doi.org/10.1016/s1535-6108(03)00003-5
Abstract
No abstract availableThis publication has 39 references indexed in Scilit:
- The roles of FLT3 in hematopoiesis and leukemiaBlood, 2002
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsThe New England Journal of Medicine, 2002
- Gene expression profiling predicts clinical outcome of breast cancerNature, 2002
- MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemiaNature Genetics, 2001
- Activity of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in the Blast Crisis of Chronic Myeloid Leukemia and Acute Lymphoblastic Leukemia with the Philadelphia ChromosomeThe New England Journal of Medicine, 2001
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitorsImmunity, 1995
- Fusion of the Leucine Zipper Gene HLF to the E2A Gene in Human Acute B-Lineage LeukemiaScience, 1992
- A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populationsCell, 1991
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987